Biotechnology • Pharmaceuticals • Clean Tech

Over the last decade, Nathaniel David, Ph.D. has co-founded five technology companies that have collectively raised more than $800 million in financing and currently employ over 350 scientists, engineers, and business people. Teaming with ARCH in 2009, Dr. David is building new companies that create disruptive technologies to address global-scale problems.

During the last year of his doctoral work (1998) at the University of California, Berkeley, he co-founded Syrrx, which was acquired in 2005 by Takeda Pharmaceuticals. The first drug to arise from Syrrx’s research programs (ALOGLIPTIN, a DPP4 inhibitor for the treatment of type 2 diabetes) has been approved in Japan and the US and is projected to have worldwide sales in excess of $2B. In 2003, Dr. David co-founded Achaogen, an antibiotic discovery company developing a potent anti-gram negative antibiotic now in Phase II clinical development. Teaming up with a group of former Amgen employees, in 2005 he co-founded Kythera Biopharmaceuticals (NASDAQ: KYTH), an aesthetic medical firm, where he served for four years as Chief Science Officer, a role in which he managed all pre-clinical drug discovery efforts. The company has multiple drug candidates in clinical trials and completed its IPO in 2012.

In the clean technology arena, Dr. David is co-founder of Sapphire Energy and Kilimanjaro Energy.

Dr. David holds numerous pending and issued patents in fields such as nanovolume crystallography, antibiotic resistance, and aesthetic medicine. He serves on the board of directors of Kilimanjaro Energy, Kythera Biopharmaceuticals, and Sapphire Energy is a member of the board of trustees of the University of California Foundation and the Buck Institute for Research on Aging. Dr. David was named one of the Top 100 innovators in the world under 35 by the MIT Technology Review.

Dr. David holds a Ph.D. from the University of California, Berkeley in Molecular and Cellular Biology and an A.B. in Biology from Harvard University.